Detail akcie Heron Therapeutics online

Business Summary: Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. It creates and commercializes a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. Its acute care product portfolio includes ZYNRELEF and APONVIE. Its oncology care product portfolio includes CINVANTI and SUSTOL. ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is an intravenous formulation of a substance P/neurokinin-1 (NK1) receptor antagonist indicated for postoperative nausea and vomiting (PONV). CINVANTI is an IV formulation of aprepitant, a substance NK1 receptor antagonist. SUSTOL is an extended-release 5-HT3 receptor antagonist for the prevention of acute and delayed nausea and vomiting.
Financial Summary: BRIEF: For the three months ended 31 March 2025, Heron Therapeutics Inc revenues increased 12% to $38.9M. Net income totaled $2.6M vs. loss of $3.2M. Revenues reflect ZYNRELEF segment increase of 60% to $8M, APONVIE segment increase from $425K to $2.3M. Net Income reflects General and administrative -Balancing decrease of 15% to $11.1M (expense), Labor & Related Expenses in R&D decrease of 51% to $1.2M (expense).